Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
CLYM Quote, Financials, Valuation and Earnings
Last price:
$4.88
Seasonality move
:
-22.23%
Day range:
$4.50 - $4.96
52-week range:
$1.05 - $5.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.87x
Volume:
323K
Avg. volume:
1.8M
1-year change:
144.95%
Market cap:
$330.7M
Revenue:
--
EPS (TTM):
-$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
-- | -$0.15 | -- | -55.88% | $9.60 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
$4.85 | $9.60 | $330.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
0.33% | 2.637 | 0.42% | 17.56x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
-$29K | -$14.9M | -25.66% | -25.72% | -- | -$12.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Climb Bio, Inc. vs. Competitors
-
Which has Higher Returns CLYM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of -255.85%. Climb Bio, Inc.'s return on equity of -25.72% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CLYM or NBY?
Climb Bio, Inc. has a consensus price target of $9.60, signalling upside risk potential of 97.94%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Climb Bio, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Climb Bio, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.6 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CLYM or NBY More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CLYM or NBY?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or NBY?
Climb Bio, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Climb Bio, Inc.'s net income of -$12.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns CLYM or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of --. Climb Bio, Inc.'s return on equity of -25.72% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About CLYM or NNVC?
Climb Bio, Inc. has a consensus price target of $9.60, signalling upside risk potential of 97.94%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than Climb Bio, Inc., analysts believe NanoViricides, Inc. is more attractive than Climb Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.6 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is CLYM or NNVC More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock CLYM or NNVC?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or NNVC?
Climb Bio, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Climb Bio, Inc.'s net income of -$12.9M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns CLYM or OGEN?
Oragenics, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of --. Climb Bio, Inc.'s return on equity of -25.72% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CLYM or OGEN?
Climb Bio, Inc. has a consensus price target of $9.60, signalling upside risk potential of 97.94%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than Climb Bio, Inc., analysts believe Oragenics, Inc. is more attractive than Climb Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.6 0 0 OGENOragenics, Inc.1 0 0 -
Is CLYM or OGEN More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CLYM or OGEN?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or OGEN?
Climb Bio, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Climb Bio, Inc.'s net income of -$12.9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CLYM or PTN?
Palatin Technologies has a net margin of -- compared to Climb Bio, Inc.'s net margin of --. Climb Bio, Inc.'s return on equity of -25.72% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CLYM or PTN?
Climb Bio, Inc. has a consensus price target of $9.60, signalling upside risk potential of 97.94%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Climb Bio, Inc., analysts believe Palatin Technologies is more attractive than Climb Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.6 0 0 PTNPalatin Technologies0 0 0 -
Is CLYM or PTN More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CLYM or PTN?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or PTN?
Climb Bio, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Climb Bio, Inc.'s net income of -$12.9M is higher than Palatin Technologies's net income of --. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CLYM or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of --. Climb Bio, Inc.'s return on equity of -25.72% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CLYM or TOVX?
Climb Bio, Inc. has a consensus price target of $9.60, signalling upside risk potential of 97.94%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Climb Bio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Climb Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.6 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CLYM or TOVX More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CLYM or TOVX?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or TOVX?
Climb Bio, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Climb Bio, Inc.'s net income of -$12.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
